Overview

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Status:
Active, not recruiting

Trial end date:
2022-06-28

Target enrollment:

Participant gender:

Summary

This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Antibodies, Monoclonal
Avelumab
Axitinib